The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview

Added Goldsby et al. as reference 47 and level of evidence 3iiiDi.

Added text to state that the cumulative risk of developing a secondary solid tumor at 10 years after diagnosis appears to be about 1.8%, although this may be higher with longer follow-up.

Ewing Tumor of Bone: Recurrent Tumors

Added Gardner et al. as reference 11 and level of evidence 3iiiDiii.

Added Gilman et al. as reference 13.

Added Eapen as reference 14.

Added text to state that COG-ADVL0821 is a phase II trial of cixutumumab, an anti-IGF1 receptor monoclonal antibody.

Back to Top

< Previous Section  |  Next Section >